Eugene Schneider Sells 6,179 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eugene Schneider sold 6,179 shares of the stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $83.45, for a total value of $515,637.55. Following the transaction, the executive vice president directly owned 69,702 shares of the company’s stock, valued at $5,816,631.90. This trade represents a 8.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Eugene Schneider also recently made the following trade(s):

• On Friday, January 16th, Eugene Schneider sold 9,302 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.59, for a total transaction of $703,138.18.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ IONS opened at $84.59 on Wednesday. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The business’s 50 day moving average price is $80.42 and its two-hundred day moving average price is $67.14. The company has a market cap of $13.70 billion, a PE ratio of -50.05 and a beta of 0.29. Ionis Pharmaceuticals, Inc. has a twelve month low of $23.95 and a twelve month high of $86.15.

Wall Street Analyst Weigh In

A number of research analysts recently commented on IONS shares. Royal Bank Of Canada upped their price target on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Morgan Stanley increased their target price on Ionis Pharmaceuticals from $90.00 to $94.00 and gave the stock an “overweight” rating in a research note on Thursday, October 30th. Wall Street Zen downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Raymond James Financial reissued a “strong-buy” rating and set a $89.00 target price (up previously from $85.00) on shares of Ionis Pharmaceuticals in a report on Thursday, October 30th. Finally, Bank of America upped their price target on shares of Ionis Pharmaceuticals from $86.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.45.

Key Headlines Impacting Ionis Pharmaceuticals

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: Several Wall Street firms have raised targets or maintained upbeat ratings recently (Bank of America, Oppenheimer, Raymond James), which supports upside expectations and helps underpin the stock. MarketBeat IONS coverage
• Positive Sentiment: Some institutions increased or established positions in Q4 (e.g., Pictet, M&T Bank, Comerica), signaling continued institutional interest and reducing concern that sales are systemically negative. Institutional holdings details
• Neutral Sentiment: Insiders still retain large stakes after the trades (CEO and several EVPs continue to hold meaningful share counts), which can indicate rebalancing rather than full exits. CEO SEC filing
• Negative Sentiment: CEO Brett P. Monia sold 62,970 shares (~$5.2M) at ~\$82.72, reducing his stake by ~18%. A sale of this magnitude by the CEO is likely weighing on near‑term sentiment. CEO Filing
• Negative Sentiment: Multiple executive VPs (including C. Frank Bennett, Brian Birchler, Eric Swayze, Patrick O’Neil, Elizabeth Hougen, Eugene Schneider) sold ~5.9–7.0k shares each in late January at low‑$80s prices. The pattern of coordinated small‑block insider sales increases share supply and can pressure momentum traders. Bennett Filing

Institutional Investors Weigh In On Ionis Pharmaceuticals

A number of large investors have recently modified their holdings of IONS. CWM LLC lifted its position in shares of Ionis Pharmaceuticals by 7.3% during the 3rd quarter. CWM LLC now owns 2,488 shares of the company’s stock worth $163,000 after buying an additional 170 shares during the last quarter. Wedmont Private Capital raised its stake in Ionis Pharmaceuticals by 3.2% during the fourth quarter. Wedmont Private Capital now owns 5,536 shares of the company’s stock worth $460,000 after acquiring an additional 173 shares in the last quarter. Golden State Wealth Management LLC raised its stake in Ionis Pharmaceuticals by 198.4% during the third quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after acquiring an additional 250 shares in the last quarter. Public Employees Retirement System of Ohio lifted its holdings in shares of Ionis Pharmaceuticals by 0.6% in the third quarter. Public Employees Retirement System of Ohio now owns 48,545 shares of the company’s stock worth $3,176,000 after acquiring an additional 301 shares during the last quarter. Finally, Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.